Applications of MALDI-TOF mass spectrometry in clinical proteomics

References

• Crutchfield CA, Thomas SN, Sokoll LJ, et al. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 2016;13:1.
   PubMed Web of Science ®Google Scholar
• Latosinska A, Frantzi M, Vlahou A, et al. Clinical proteomics for precision medicine: the bladder cancer case. PROTEOMICS–Clinical Appl. 2018;1:1700074.
   Google Scholar
• Cho Y-T, Su H, Wu W-J, et al. Chapter six-biomarker characterization by MALDI–TOF/MS. Adv Clin Chem. 2015;69:209–254.
   PubMed Web of Science ®Google Scholar
• Patel TS, Kaakeh R, Nagel JL, et al. Cost analysis of implementing matrix-assisted laser desorption ionization–time of flight mass spectrometry plus real-time antimicrobial stewardship intervention for bloodstream infections. J Clin Microbiol. 2017;55:60–67.
   PubMed Web of Science ®Google Scholar
• Karas M, Bachmann D, Hillenkamp F. Influence of the wavelength in high-irradiance ultraviolet laser desorption mass spectrometry of organic molecules. Anal Chem. 1985;57:2935–2939.
   Web of Science ®Google Scholar
• Tanaka K, Waki H, Ido Y, et al. Protein and polymer analyses up to m/z 100 000 by laser ionization time‐of‐flight mass spectrometry. Rapid Commun in Mass Spectrometry. 1988;2:151–153.
   Google Scholar
• Duncan MW, Nedelkov D, Walsh R, et al. Applications of MALDI mass spectrometry in clinical chemistry. Clin Chem. 2016;62:134–143.
   PubMed Web of Science ®Google Scholar
• Garaguso I, Borlak J. Matrix layer sample preparation: an improved MALDI‐MS peptide analysis method for proteomic studies. Proteomics. 2008;8:2583–2595.
   PubMed Web of Science ®Google Scholar
• de Hoffmann E, Stroobant V. Mass spectrometry: principles and applications. John Wiley & Sons; 2007.
   Google Scholar
• Mamyrin B, Karataev V, Shmikk D, et al. The mass-reflectron. A new nonmagnetic time-of-flight high resolution mass-spectrometer. Zhurnal Ehksperimental’noj I Teoreticheskoj Fiziki. 1973;64:82–89.
   Google Scholar
• Mamyrin B. Laser assisted reflectron time-of-flight mass spectrometry. Int J Mass Spectrom Ion Process. 1994;131:1–19.
   Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics.Nature. 2003; p.-198–207.
   Google Scholar
• Gregorich ZR, Ge Y. Top‐down proteomics in health and disease: challenges and opportunities. Proteomics. 2014;14:1195–1210.
   PubMed Web of Science ®Google Scholar
• Oliveira BM, Coorssen JR, Martins-de-Souza D. 2DE: the phoenix of proteomics. J Proteomics. 2014;104:140–150.
   PubMed Web of Science ®Google Scholar
• Liu Z, Schey KL. Optimization of a MALDI TOF-TOF mass spectrometer for intact protein analysis. J Am Soc Mass Spectrom. 2005;16:482–490.
   PubMed Web of Science ®Google Scholar
• Stöcklin R, Vu L, Vadas L, et al. A stable isotope dilution assay for the in vivo determination of insulin levels in humans by mass spectrometry. Diabetes. 1997;46:44–50.
   PubMed Web of Science ®Google Scholar
• Stöcklin R, Arrighi J-F, van Hoang- K, et al. Positive and negative labeling of human proinsulin, insulin, and C-peptide with stable isotopes: new tools for in vivo pharmacokinetic and metabolic studies. Methods Mol Bio. 2000;146:293–315.
   PubMedGoogle Scholar
• Cramer R, Gobom J, Nordhoff E. High-throughput proteomics using matrix-assisted laser desorption/ionization mass spectrometry. Expert Rev Proteomics. 2005;2:407–420.
   PubMed Web of Science ®Google Scholar
• Marvin LF, Roberts MA, Fay LB. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clinica Chimica Acta. 2003;337:11–21.
   PubMed Web of Science ®Google Scholar
• Beardsley RL, Reilly JP. Optimization of guanidination procedures for MALDI mass mapping. Anal Chem. 2002;74:1884–1890.
   PubMed Web of Science ®Google Scholar
• Ng EW, Wong MY, Poon TC. Advances in MALDI mass spectrometry in clinical diagnostic applications. 2014; 336:139-175.
   Google Scholar
• Banach T, Ł A, Wyłupek D, et al. Applicability of 2D gel electrophoresis and liquid chromatography in proteomic analysis of urine using mass spectrometry MALDI-TOF. Pol J Vet Sci. 2013;16:587–592.
   PubMed Web of Science ®Google Scholar
• Rosa N, Correia MJ, Arrais JP, et al. From the salivary proteome to the OralOme: comprehensive molecular oral biology. Arch Oral Biol. 2012;57:853–864.
   PubMed Web of Science ®Google Scholar
• Al-Tarawneh SK, Border MB, Dibble CF, et al. Defining salivary biomarkers using mass spectrometry-based proteomics: a systematic review. Omics: J Integrative Biol. 2011;15:353–361.
   PubMed Web of Science ®Google Scholar
• Hu S, Loo JA, Wong DT. Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics. 2007;4:531–538.
   PubMed Web of Science ®Google Scholar
• Castagnola M, Cabras T, Iavarone F, et al. The human salivary proteome: a critical overview of the results obtained by different proteomic platforms. Expert Rev Proteomics. 2012;9:33–46.
   PubMed Web of Science ®Google Scholar
• Hagan S, Martin E, Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. EPMA J. 2016;7:15.
   PubMed Web of Science ®Google Scholar
• Gilany K, Minai-Tehrani A, Savadi-Shiraz E, et al. Exploring the human seminal plasma proteome: an unexplored gold mine of biomarker for male infertility and male reproduction disorder. J Reproduction & Infertility. 2015;16:61–71.
   PubMedGoogle Scholar
• Xu X, Veenstra TD. Analysis of biofluids for biomarker research. PROTEOMICS-Clinical Appl. 2008;2:1403–1412.
   PubMed Web of Science ®Google Scholar
• Veenstra TD, Conrads TP, Hood BL, et al. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics. 2005;4:409–418.
   PubMed Web of Science ®Google Scholar
• Paik Y-K, Kim H, Lee E-Y, et al. Overview and introduction to clinical proteomics. Methods Mol Bio. 2008;428:1–31.
   PubMedGoogle Scholar
• Lapolla A, Fedele D, Aronica R, et al. A highly specific method for the characterization of glycation and glyco‐oxidation products of globins. Rapid Commun in Mass Spectrometry. 1997;11:613–617.
   PubMed Web of Science ®Google Scholar
• Biroccio A, Urbani A, Massoud R, et al. A quantitative method for the analysis of glycated and glutathionylated hemoglobin by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Anal Biochem. 2005;336:279–288.
   PubMed Web of Science ®Google Scholar
• Shiea J, Cho YT, Lin YH, et al. Using matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry to rapidly screen for albuminuria. Rapid Commun Mass Spectrometry. 2008;22:3754–3760.
   PubMedGoogle Scholar
• Iles RK, Shahpari ME, Cuckle H, et al. Direct and rapid mass spectral fingerprinting of maternal urine for the detection of Down syndrome pregnancy. Clin Proteomics. 2015;12:9.
   PubMed Web of Science ®Google Scholar
• Cho C-KJ, Diamandis EP. Application of proteomics to prenatal screening and diagnosis for aneuploidies. Clin Chem Lab Med. 2011;49(1):33–41.
   PubMed Web of Science ®Google Scholar
• Kamanna S, Henry J, Voelcker NH, et al. Direct identification of forensic body fluids using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Int J Mass Spectrom. 2016;397:18–26.
   Web of Science ®Google Scholar
• Guinan T, Kirkbride P, Pigou PE, et al. Surface‐assisted laser desorption ionization mass spectrometry techniques for application in forensics. Mass Spectrom Rev. 2015;34:627–640.
   PubMed Web of Science ®Google Scholar
• Ferrari L, Seraglia R, Rossi CR, et al. Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun Mass Spectrometry. 2000;14:1149–1154.
   PubMed Web of Science ®Google Scholar
• Musharraf SG, Hashmi N, Choudhary MI, et al. Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS. Biomarkers. 2012;17:223–230.
   PubMed Web of Science ®Google Scholar
• Klupczynska A, Swiatly A, Hajduk J, et al. Identification of serum peptidome signatures of non-small cell lung cancer. Int J Mol Sci. 2016;17:410.
   PubMed Web of Science ®Google Scholar
• Widlak P, Pietrowska M, Polanska J, et al. Serum mass profile signature as a biomarker of early lung cancer. Lung Cancer. 2016;99:46–52.
   PubMed Web of Science ®Google Scholar
• Swiatly A, Horala A, Hajduk J, et al. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer. BMC Cancer. 2017;17:472.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Goss G, Soria J-C, et al. Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017;109:101–108.
   PubMed Web of Science ®Google Scholar
• Wolter M, Rower C, Koy C, et al. Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature. J Proteomics. 2016;149:44–52.
   PubMed Web of Science ®Google Scholar
• Meng Q, Ge S, Yan W, et al. Screening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using MALDI-TOF MS. Proteomics Clin Appl. 2017;11:3–4.
   Web of Science ®Google Scholar
• Wang H, Luo C, Zhu S, et al. Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts. Oncotarget. 2017;8:59376–59386.
   PubMedGoogle Scholar
• Rovithi M, Lind JSW, Pham TV, et al. Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer. Proteomics Clin Appl. 2016;10:743–749.
   PubMed Web of Science ®Google Scholar
• Snyder CM, Alley WR Jr., Campos MI, et al. Complementary glycomic analyses of sera derived from colorectal cancer patients by MALDI-TOF-MS and microchip electrophoresis. Anal Chem. 2016;88:9597–9605.
   PubMed Web of Science ®Google Scholar
• Oran PE, Trenchevska O, Nedelkov D, et al. Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay. PLoS One. 2014;9:e92801.
   PubMed Web of Science ®Google Scholar
• Guu S-Y, Lin T-H, Chang S-C, et al. Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients. PLoS One. 2017;12:e0178927.
   PubMed Web of Science ®Google Scholar
• Yao J, Sun N, Wang J, et al. Rapid synthesis of titanium(IV)-immobilized magnetic mesoporous silica nanoparticles for endogenous phosphopeptides enrichment. Proteomics. 2017; 17: 1600320
   Google Scholar
• Lapolla A, Molin L, Sechi A, et al. A further investigation on a MALDI-based method for evaluation of markers of renal damage. J Mass Spectrometry: JMS. 2009;44:1754–1760.
   PubMed Web of Science ®Google Scholar
• Cho YT, Chen CW, Chen MP, et al. Diagnosis of albuminuria by tryptic digestion and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Clin Chim Acta. 2013;420:76–81.
   PubMed Web of Science ®Google Scholar
• Bonesso L, Piraud M, Caruba C, et al. Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry. Orphanet J Rare Dis. 2014;9:19.
   PubMed Web of Science ®Google Scholar
• Lapolla A, Porcu S, Traldi P. Mass spectrometry for diabetic nephropathy monitoring: new effective tools for physicians. ISRN Endocrinol. 2012;2012:768159.
   PubMedGoogle Scholar
• Bryan RT, Wei W, Shimwell NJ, et al. Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. Proteomics Clin Appl. 2011;5:493–503.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang S, Zhang M. Identification of urine biomarkers associated with lung adenocarcinoma. Oncotarget. 2017;8:38517–38529.
   PubMedGoogle Scholar
• Segawa S, Sawai S, Murata S, et al. Direct application of MALDI-TOF mass spectrometry to cerebrospinal fluid for rapid pathogen identification in a patient with bacterial meningitis. Clin Chim Acta. 2014;435:59–61.
   PubMed Web of Science ®Google Scholar
• Liguori M, Qualtieri A, Tortorella C, et al. Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One. 2014;9:e103984.
   PubMed Web of Science ®Google Scholar
• Pieragostino D, Del Boccio P, Di Ioia M, et al. Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. Proteomics. 2013;13:1002–1009.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Mja K-S, Pham TV, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler. 2011;17:838–850.
   PubMed Web of Science ®Google Scholar
• Karlsson I, Ndreu L, Quaranta A, et al. Glycosylation patterns of selected proteins in individual serum and cerebrospinal fluid samples. J Pharm Biomed Anal. 2017;145:431–439.
   PubMed Web of Science ®Google Scholar
• Palmigiano A, Messina A, Bua RO, et al. CSF N-glycomics using MALDI MS techniques in Alzheimer’s disease. Methods Mol Biol. 2018;1750:75–91.
   PubMedGoogle Scholar
• Palmigiano A, Barone R, Sturiale L, et al. CSF N-glycoproteomics for early diagnosis in Alzheimer’s disease. J Proteomics. 2016;131:29–37.
   PubMed Web of Science ®Google Scholar
• Prodan A, Brand H, Imangaliyev S, et al. A study of the variation in the salivary peptide profiles of young healthy adults acquired using MALDI-TOF MS. PLoS One. 2016;11:e0156707.
   PubMed Web of Science ®Google Scholar
• Ao S, Sun X, Shi X, et al. Longitudinal investigation of salivary proteomic profiles in the development of early childhood caries. J Dent. 2017;61:21–27.
   PubMed Web of Science ®Google Scholar
• Hajduk J, Matysiak J, Kokot ZJ. Challenges in biomarker discovery with MALDI-TOF MS. Clinica Chimica Acta. 2016;458:84–98.
   PubMed Web of Science ®Google Scholar
• Gatlin CL, White KY, Tracy MB, et al. Enhancement in MALDI‐TOF MS analysis of the low molecular weight human serum proteome. J Mass Spectrometry. 2011;46:85–89.
   PubMed Web of Science ®Google Scholar
• Padoan A, Basso D, la Malfa M, et al. Reproducibility in urine peptidome profiling using MALDI‐TOF. Proteomics. 2015;15:1476–1485.
   PubMed Web of Science ®Google Scholar
• Callesen AK, Madsen JS, Vach W, et al. Serum protein profiling by solid phase extraction and mass spectrometry: a future diagnostics tool? Proteomics. 2009;9:1428–1441.
   PubMed Web of Science ®Google Scholar
• Callesen AK, Madsen JS, Vach W, et al. Reproducibility of serum protein profiling by systematic assessment using solid‐phase extraction and matrix‐assisted laser desorption/ionization mass spectrometry. Rapid Commun in Mass Spectrometry. 2008;22:291–300.
   PubMed Web of Science ®Google Scholar
• Chen Y-N, Du H-Y, Shi Z-Y, et al. Serum proteomic profiling for autism using magnetic bead-assisted matrix-assisted laser desorption ionization time-of-flight mass spectrometry: a pilot study. World J Pediatrics. 2018;14:233–237.
   PubMed Web of Science ®Google Scholar
• Qi W J, Jiang JH, Li X, et al. Magnetic bead-based salivary peptidome profiling for accelerated osteogenic orthodontic treatments. Chin J Dent Res. 2018;21:41–49.
   PubMed Web of Science ®Google Scholar
• Zeng X, Zhao L, Li Z, et al. Impact of experimental and demographic variables in serum peptide profiling based on magnetic bead and MALDI-TOF mass spectrometry. Clinica Chimica Acta. 2011;412:112–119.
   PubMed Web of Science ®Google Scholar
• Terracciano R, Preianò M, Palladino GP, et al. Peptidome profiling of induced sputum by mesoporous silica beads and MALDI‐TOF MS for non‐invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics. 2011;11:3402–3414.
   PubMed Web of Science ®Google Scholar
• Klont F, Nh TH, Pt H, et al. Assuring consistent performance of an insulin-like growth factor 1 MALDImmunoassay by monitoring measurement quality indicators. Anal Chem. 2017;89:6188–6195.
   PubMed Web of Science ®Google Scholar
• Li H, Popp R, Frohlich B, et al. Peptide and Protein Quantification Using Automated Immuno-MALDI (iMALDI). J. Vis. Exp. 2017;e55933.
   Google Scholar
• Wang J, Yao J, Sun N, et al. Facile synthesis of thiol-polyethylene glycol functionalized magnetic titania nanomaterials for highly efficient enrichment of N-linked glycopeptides. J Chromatogr. 2017;1512:1–8.
   Web of Science ®Google Scholar
• Kanshin E, Michnick S, Thibault P, editors Sample preparation and analytical strategies for large-scale phosphoproteomics experiments. Semin Cell Dev Biol. 2012;23:843-853.
   Google Scholar
• Verrills NM. Clinical proteomics: present and future prospects. Clin Biochemist Rev. 2006;27:99–116.
   PubMedGoogle Scholar
• Law K, Larkin JR. Recent advances in SALDI-MS techniques and their chemical and bioanalytical applications. Anal Bioanal Chem. 2011;399:2597–2622.
   PubMed Web of Science ®Google Scholar
• Guinan T, Ronci M, Vasani R, et al. Comparison of the performance of different silicon-based SALDI substrates for illicit drug detection. Talanta. 2015;132:494–502.
   PubMed Web of Science ®Google Scholar
• Guinan T, Ronci M, Kobus H, et al. Rapid detection of illicit drugs in neat saliva using desorption/ionization on porous silicon. Talanta. 2012;99:791–798.
   PubMed Web of Science ®Google Scholar
• Najam-ul-Haq M, Rainer M, Trojer L, et al. Alternative profiling platform based on MELDI and its applicability in clinical proteomics. Expert Rev Proteomics. 2007;4:447–452.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet. 2002;359:572–577.
   PubMed Web of Science ®Google Scholar
• Alvarez AM, Neubeck S, Parra S, et al. Serum protein profile in women with pregnancy morbidity associated with antiphospholipid syndrome. J Hum Reprod Sci. 2017;10:10–17.
   PubMedGoogle Scholar
• Baudin B, Bruneel A, Poupon R, et al. Serum proteomic signatures as biomarkers of primary biliary cirrhosis diagnosis and prognosis. Ann Biol Clin (Paris). 2016;74:607–612.
   PubMed Web of Science ®Google Scholar
• de Seny D, Cobraiville G, Leprince P, et al. Biomarkers of inflammation and innate immunity in atrophic nonunion fracture. J Transl Med. 2016;14:258.
   PubMed Web of Science ®Google Scholar
• Maruwaka M, Yoshikawa K, Okamoto S, et al. Biomarker research for moyamoya disease in cerebrospinal fluid using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. J Stroke Cerebrovasc Dis. 2015;24:104–111.
   PubMed Web of Science ®Google Scholar
• Ardito F, Giuliani M, Perrone D, et al. Expression of salivary biomarkers in patients with oral mucositis: evaluation by SELDI‐TOF/MS. Oral Dis. 2016;22:209–219.
   PubMed Web of Science ®Google Scholar
• Feuerstein I, Najam-ul-Haq M, Rainer M, et al. Material-enhanced laser desorption/ionization (MELDI)—A new protein profiling tool utilizing specific carrier materials for time of flight mass spectrometric analysis. J Am Soc Mass Spectrom. 2006;17:1203–1208.
   PubMed Web of Science ®Google Scholar
• Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997;69:4751–4760.
   PubMed Web of Science ®Google Scholar
• Baker TC, Han J, Borchers CH. Recent advancements in matrix-assisted laser desorption/ionization mass spectrometry imaging. Curr Opin Biotechnol. 2017;43:62–69.
   PubMed Web of Science ®Google Scholar
• Pallua J, Schaefer G, Bittner L, et al. Matrix-Assisted Laser Desorption-Ionization Imaging Mass Spectrometry for Direct Tissue Analysis. LC, GC North America. 2011; (Spec. Iss.):21-28.
   Google Scholar
• Zhou R, Basile F. Plasmonic-thermal decomposition/digestion of proteins: a rapid on-surface protein digestion technique for mass spectrometry imaging. Anal Chem. 2017;89:8704–8712.
   PubMed Web of Science ®Google Scholar
• Rodrigo MAM, Zitka O, Krizkova S, et al. MALDI-TOF MS as evolving cancer diagnostic tool: a review. J Pharm Biomed Anal. 2014;95:245–255.
   PubMed Web of Science ®Google Scholar
• Cole LM, Clench MR. Mass spectrometry imaging tools in oncology. Biomarkers: Biochem Indicators Exposure, Response, Susceptibility to Chem. 2015;9:863–868.
   Google Scholar
• Kim HK, Reyzer ML, Choi IJ, et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res. 2010;9:4123–4130.
   PubMed Web of Science ®Google Scholar
• Rebours V, le Faouder J, Laouirem S, et al. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms. Pancreatology. 2014;14:117–124.
   PubMed Web of Science ®Google Scholar
• Balluff B, Frese CK, Maier SK, et al. De novo discovery of phenotypic intratumour heterogeneity using imaging mass spectrometry. J Pathol. 2015;235:3–13.
   PubMed Web of Science ®Google Scholar
• Balluff B, Rauser S, Ebert MP, et al. Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. Gastroenterology. 2012;143(544–9):e2.
   Google Scholar
• Rahman SJ, Gonzalez AL, Li M, et al. Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res. 2011;71:3009–3017.
   PubMed Web of Science ®Google Scholar
• Marko-Varga G, Fehniger TE, Rezeli M, et al. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J Proteomics. 2011;74:982–992.
   PubMed Web of Science ®Google Scholar
• Steurer S, Borkowski C, Odinga S, et al. MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large‐scale tissue microarrays. Int J Cancer. 2013;133:920–928.
   PubMed Web of Science ®Google Scholar
• Bonnel D, Longuespee R, Franck J, et al. Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Anal Bioanal Chem. 2011;401:149–165.
   PubMed Web of Science ®Google Scholar
• Pallua JD, Schaefer G, Seifarth C, et al. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. J Proteomics. 2013;91:500–514.
   PubMed Web of Science ®Google Scholar
• Schwamborn K, Kriegsmann M, Weichert W. MALDI imaging mass spectrometry—from bench to bedside. Biochimica Et Biophysica Acta (Bba)-Proteins Proteomics. 2017;1865:776–783.
   PubMedGoogle Scholar
• Pietrowska M, Diehl HC, Mrukwa G, et al. Molecular profiles of thyroid cancer subtypes: classification based on features of tissue revealed by mass spectrometry imaging. Biochimica Et Biophysica Acta (Bba)-Proteins Proteomics. 2017;1865:837–845.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang J, Guo F, et al. Identification of apolipoprotein CI peptides as a potential biomarker and its biological roles in breast cancer. Med Sci Monitor: Int Med J Exp Clini Res. 2016;22:1152.
   Google Scholar
• Sugihara Y, Watanabe K-I VÁ. Novel insights in drug metabolism by MS imaging. Bioanalysis. 2016;8:575–588.
   PubMed Web of Science ®Google Scholar
• Schubert KO, Weiland F, Baune BT, et al. The use of MALDI‐MSI in the investigation of psychiatric and neurodegenerative disorders: A review. Proteomics. 2016;16:1747–1758.
   PubMed Web of Science ®Google Scholar
• Hanrieder J, Malmberg P, Ewing AG. Spatial neuroproteomics using imaging mass spectrometry. Biochimica Et Biophysica Acta (Bba)-Proteins Proteomics. 2015;1854:718–731.
   PubMedGoogle Scholar
• Llombart V, Trejo SA, Bronsoms S, et al. Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. J Proteomics. 2017;152:243–253.
   PubMed Web of Science ®Google Scholar
• Bailey MJ, Bradshaw R, Francese S, et al. Rapid detection of cocaine, benzoylecgonine and methylecgonine in fingerprints using surface mass spectrometry. Analyst. 2015;140:6254–6259.
   PubMed Web of Science ®Google Scholar
• Lauzon N, Dufresne M, Chauhan V, et al. Development of laser desorption imaging mass spectrometry methods to investigate the molecular composition of latent fingermarks. J Am Soc Mass Spectrom. 2015;26:878–886.
   PubMed Web of Science ®Google Scholar
• He Y, Li H, Lu X, et al. Mass spectrometry biotyper system identifies enteric bacterial pathogens directly from colonies grown on selective stool culture media. J Clin Microbiol. 2010;48:3888–3892.
   PubMed Web of Science ®Google Scholar
• Singhal N, Kumar M, Kanaujia PK, et al. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791.
   PubMed Web of Science ®Google Scholar
• Angeletti S. Matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) in clinical microbiology. J Microbiol Methods. 2017;138:20–29.
   PubMed Web of Science ®Google Scholar
• Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med. 2012;137:1247–1254.
   PubMed Web of Science ®Google Scholar
• Gurard-Levin ZA, Scholle MD, Eisenberg AH, et al. High-throughput screening of small molecule libraries using SAMDI mass spectrometry. ACS Comb Sci. 2011;13:347–35.
   PubMed Web of Science ®Google Scholar
• Papac DI, Shahrokh Z. Mass spectrometry innovations in drug discovery and development. Pharm Res. 2001;18:131–145.
   PubMed Web of Science ®Google Scholar
• VanderPorten EC, Scholle MD, Sherrill J, et al. Identification of small-molecule noncovalent binders utilizing SAMDI technology. SLAS DISCOVERY: Advancing Life Sciences R&D. 2017;22:1211–1217.
   PubMed Web of Science ®Google Scholar
• Calandra E, Posocco B, Crotti S, et al. Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements. Anal Bioanal Chem. 2016;408:5369–5377.
   PubMed Web of Science ®Google Scholar
• Muddiman DC, Gusev AI, Proctor A, et al. Quantitative measurement of cyclosporin A in blood by time-of-flight mass spectrometry. Anal Chem. 1994;66:2362–2368.
   PubMed Web of Science ®Google Scholar
• Urbani A, Federici G. I Immunosuppressant monitoring by maldi mass spectrometry. European Patent Application; 2012: EP2426499A1
   Google Scholar
• Su A-K, Liu J-T, Lin C-H. Rapid drug-screening of clandestine tablets by MALDI-TOF mass spectrometry. Talanta. 2005;67:718–724.
   PubMed Web of Science ®Google Scholar
• Gut Y, Boiret M, Bultel L, et al. Application of chemometric algorithms to MALDI mass spectrometry imaging of pharmaceutical tablets. J Pharm Biomed Anal. 2015;105:91–100.
   PubMed Web of Science ®Google Scholar
• Thoren KL, editor Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol. 2018;55:41-43
   Google Scholar
• Song W, Wang N, Li W, et al. Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia. Oncol Lett. 2013;6:1453–1460.
   PubMed Web of Science ®Google Scholar
• Bai J, He A, Zhang W, et al. Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling. Proteome Sci. 2013;11:39.
   PubMed Web of Science ®Google Scholar
• Rappsilber J, Moniatte M, Nielsen ML, et al. Experiences and perspectives of MALDI MS and MS/MS in proteomic research. Int J Mass Spectrom. 2003;226:223–237.
   Web of Science ®Google Scholar
• Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem. 2007;53:852–858.
   PubMed Web of Science ®Google Scholar
• Greco V, Piras C, Pieroni L, et al. Direct Assessment of Plasma/Serum Sample Quality for Proteomics Biomarker Investigation. Serum/Plasma Proteomics: Methods and Protocols. 2017; 1619:3–21.
   Google Scholar
• Percy AJ, Parker CE, Borchers CH. Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. Bioanalysis. 2013;5:2837–2856.
   PubMed Web of Science ®Google Scholar
• Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics. 2006;3:409–426.
   PubMed Web of Science ®Google Scholar
• Rosenling T, Slim CL, Christin C, et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res. 2009;8:5511–5522.
   PubMed Web of Science ®Google Scholar
• Takehana S, Yoshida H, Ozawa S, et al. The effects of pre-analysis sample handling on human plasma amino acid concentrations. Clinica Chimica Acta. 2016;455:68–74.
   PubMed Web of Science ®Google Scholar
• Mateos J, Carneiro I, Corrales F, et al. Multicentric study of the effect of pre-analytical variables in the quality of plasma samples stored in biobanks using different complementary proteomic methods. J Proteomics. 2017;150:109–120.
   PubMed Web of Science ®Google Scholar
• Hassis ME, Niles RK, Braten MN, et al. Evaluating the effects of preanalytical variables on the stability of the human plasma proteome. Anal Biochem. 2015;478:14–22.
   PubMed Web of Science ®Google Scholar
• Greco V, Pieragostino D, Piras C, et al. Direct analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples. Proteomics. 2014;14:1954–1962.
   PubMed Web of Science ®Google Scholar
• Pieragostino D, Petrucci F, del Boccio P, et al. Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J Proteomics. 2010;73:579–592.
   PubMed Web of Science ®Google Scholar
• Marshall J, Kupchak P, Zhu W, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res. 2003;2:361–372.
   PubMed Web of Science ®Google Scholar
• Karsan A, Eigl BJ, Flibotte S, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005;51:1525–1528.
   PubMed Web of Science ®Google Scholar
• Preianò M, Maggisano G, Lombardo N, et al. Influence of storage conditions on MALDI‐TOF MS profiling of gingival crevicular fluid: implications on the role of S100A8 and S100A9 for clinical and proteomic based diagnostic investigations. Proteomics. 2016;16:1033–1045.
   PubMed Web of Science ®Google Scholar
• Lygirou V, Makridakis M, Vlahou A. Biological sample collection for clinical proteomics: existing SOPs. Clinical Proteomics: Methods Protocols. 2015; 1243:3–27.
   Google Scholar
• Dekker L, Dalebout J, Jenster G, et al. Reproducibility of MALDI-TOF mass spectrometry measurements on complex biofluids. AACR; 2004; 64: 817
   Google Scholar
• Duncan MW, Roder H, Hunsucker SW. Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Briefings Functional Genom Proteomics. 2008;7:355–370.
   PubMedGoogle Scholar
• Krutchinsky AN, Chait BT. On the nature of the chemical noise in MALDI mass spectra. J Am Soc Mass Spectrom. 2002;13:129–134.
   PubMed Web of Science ®Google Scholar
• van Kampen JJ, Burgers PC, de Groot R, et al. Biomedical application of MALDI mass spectrometry for small‐molecule analysis. Mass Spectrom Rev. 2011;30:101–120.
   PubMed Web of Science ®Google Scholar
• Lou X, Waal BF, Milroy LG, et al. A sample preparation method for recovering suppressed analyte ions in MALDI TOF MS. J Spectrom. 2015;50:766–770.
   PubMed Web of Science ®Google Scholar
• Bucknall M, Fung KY, Duncan MW. Practical quantitative biomedical applications of MALDI-TOF mass spectrometry. J Am Soc Mass Spectrom. 2002;13:1015–1027.
   PubMed Web of Science ®Google Scholar
• Pang RT, Johnson PJ, Chan CM, et al. Technical evaluation of MALDI-TOF mass spectrometry for quantitative proteomic profiling matrix formulation and application. Clin Proteomics. 2004;1:259.
   Google Scholar